Hemagen Diagnostics, Inc.
Hemagen Diagnostics, Inc.
Your view on HMGN
Overview
What the company does, where it operates, and who runs it.
About Hemagen Diagnostics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- William Hales
- Headquarters
- 9033 Red Branch Road, Columbia, MD, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- William Hales
- Headquarters
- 9033 Red Branch Road, Columbia, MD, US
Hemagen Diagnostics, Inc., a biotechnology company, provides human and veterinary clinical diagnostic solutions worldwide. The company develops, manufactures, and markets VIRGO, a human clinical diagnostic line of immunoassays for the diagnosis of autoimmune and infectious diseases, and acute phase proteins.
Its human diagnostics products also comprise Universal IFA components; supplies, controls and calibrators, accessories, and H-rotors; reagents, electrodes, equipment; and specialty assays, including Chagas, acute phase proteins, and cytokines.
In addition, the company provides veterinary diagnostic products, such as equipment, reagents, supplies, accessories, and electrodes in chemistry, hematology, and electrolyte areas. It sells its products directly, as well as through distributors to various laboratories, hospitals, and blood banks.
The company was founded in 1985 and is based in Columbia, Maryland.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Hemagen Diagnostics, Inc., and the rating behind it. HMGN last traded at $0.0002; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Hemagen Diagnostics, Inc.. Starting points for Hemagen Diagnostics, Inc.: EPS -$0.06, beta 0.36 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Hemagen Diagnostics, Inc.. Hemagen Diagnostics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Hemagen Diagnostics, Inc.. Trailing twelve-month EPS for Hemagen Diagnostics, Inc. stands at -$0.06. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Hemagen Diagnostics, Inc.. Hemagen Diagnostics, Inc. has reported as a listed company since 1993. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Hemagen Diagnostics, Inc. valued side by side against its closest peers. Hemagen Diagnostics, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Hemagen Diagnostics, Inc., and how their positions are changing. At a $3,100 market value, institutional positions materially move Hemagen Diagnostics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Hemagen Diagnostics, Inc. executives and directors. Shares of Hemagen Diagnostics, Inc. have traded between $0.0001 and $0.02 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Hemagen Diagnostics, Inc.. Hemagen Diagnostics, Inc. is a $3,100 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Hemagen Diagnostics, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Hemagen Diagnostics, Inc.. Coverage tracks Hemagen Diagnostics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.